G35.9
Conditions
Interventions
Group 1: 25 patients with multiple sclerosis without pain complaints, who were examined crosssectionally 2022-2025 using PREP, a CPM test paradigm and standardized questionnaires (taking about 3 hours
Sponsors
BG UK Bergmannsheil gGmbH, Neurologische Klinik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients with MS and chronic central neuropathic pain: - Confirmed diagnosis of multiple sclerosis based on the 2017 revised McDonald criteria - Presence of central neuropathic pain with symptom persistence or recurring pain episodes lasting > 3 months - Average pain intensity in the last 4 weeks =2 on the NRS (0-10) - Existing informed consent Inclusion criteria for patients with MS without chronic neuropathic pain: - Confirmed diagnosis of multiple sclerosis based on the McDonald criteria revised in 2017 - Not taking medication for the treatment of central neuropathic pain (e.g. amitryptiline, SNRI, pregabalin, lamotrigine, etc.) - Declaration of consent available
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients with MS and chronic central neuropathic pain: - Lack of informed consent - Average pain intensity in the last 4 weeks 2 (NRS 0-10) - Current pain intensity > 0 (NRS 0-10) - Insufficient German language skills or other communication problems - Neuropathies (e.g. polyneuropathy), radiculopathies or nerve lesions - Chronic pain syndromes associated with multiple sclerosis - Other chronic pain syndromes (e.g. migraine) - Polyneuropathy - Spinal stenosis - Other neuropathic pain syndromes - Epilepsy treated with anticonvulsants - Psychiatric illness treated with anticonvulsants or antidepressants with proven effect on neuropathic pain - Treatment with cannabinoid-containing preparations - Opiate use - Other severe systemic or focal CNS affection - Other central or peripheral neurological diseases - Severe cognitive or psychiatric impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| group differences in the length of N1-latency and magnitude of N1-P1-amplitude and the magnitude of CPM-effect at the time of the crosssectional examination | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of pain perception of PREP-stimuli on a numerical rating scale (NRS); sensory profile determined via bedside quantitative sensory testing (QST); Level of pain sensitivity in everyday life determined via Pain Sensitivity Questionnaire (PSQ), level of anxiety, depression and stress dtermined via Depression Anxiety Stress Scale (DASS-21), level of fatigue assessed via Fatigue Scale for Motor and Cognitive Function (FSMC); clinical neurological abnormalities assessed via classic clinical neurological examination | — |
Countries
Germany
Contacts
Public ContactElena Enax-Krumova
BG UK Bergmannsheil gGmbH, Neurologische Klinik
Outcome results
None listed